CADL - Candel Therapeutics, Inc.
IEX Last Trade
9.02
-0.010 -0.111%
Share volume: 4,967
Last Updated: Thu 26 Dec 2024 04:30:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$9.03
-0.01
-0.11%
Fundamental analysis
15%
Profitability
0%
Dept financing
12%
Liquidity
75%
Performance
15%
Performance
5 Days
0.57%
1 Month
81.82%
3 Months
25.71%
6 Months
55.75%
1 Year
685.71%
2 Year
478.95%
Key data
Stock price
$9.02
DAY RANGE
$8.69 - $9.15
52 WEEK RANGE
$1.25 - $14.60
52 WEEK CHANGE
$533.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Paul-Peter Tak
Region: US
Website: candeltx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: candeltx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Candel Therapeutics, Inc. engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer. CAN-3110, in Phase I clinical trials for the. treatment of recurrent glioblastoma, has completed Phase Ib/II clinical trials.
Recent news